Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a schiff base-forming drug.

Charo J, Lindencrona JA, Carlson LM, Hinkula J, Kiessling R.

Cancer Center Karolinska (CCK), Karolinska Hospital, R8:01, S-17176 Stockholm, Sweden. Jehad.Charo@mtc.ki.se

Effective vaccination against heterologous influenza virus infection remains elusive. Immunization with plasmid DNA (pDNA) expressing conserved genes from influenza virus is a promising approach to achieve cross-variant protection. However, despite having been described for more than a decade, pDNA vaccination still requires further optimization to be applied clinically as a standard vaccination approach. We have recently described a simple and efficient approach to enhance pDNA immunization, based on the use of tucaresol, a Schiff base-forming drug. In this report we have tested the ability of this drug to increase the protection conferred by pDNA vaccination against influenza virus infection. Our results demonstrate that a significant protection was achieved in two strains of mice by using the combination of pDNA and tucaresol. This protection was associated with an elevated humoral and cellular response and a switch in the type of the T helper cell (Th) immune response from type 2 to type 1. This vaccine combination represents a promising strategy for designing a clinical study for the protection from influenza and similar infections.